Ticker
$EQ
1 catalyst touching EQ in the last 60 days, newest first, each with the price move that followed.
- 62
Equillium clears Phase 1 trial for EQ504; dosing to begin November
Equillium received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia to initiate a Phase 1 clinical trial of EQ504, with dosing of healthy participants expected to begin by early November 2026. This represents regulatory clearance to move a drug candidate into human testing, validating the path forward for the compound, though Phase 1 trials are early-stage studies with inherent execution risk and no guarantee of efficacy outcomes.
EQ ▲SEC 8-K · 5 Oct 2026, 21:06 UTC
Information only. AURA does not give buy or sell recommendations.